Bausch Health Companies Inc.

As of June 30, 2026, Bausch Health Companies Inc. carries a market capitalization of 32.30B, placing it among publicly traded companies globally. Its enterprise value stands at 380.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bausch Health Companies Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Bausch Health Companies Inc. has 373.90M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.17, and the price-to-book ratio stands at -1.04.

As of June 30, 2026, Bausch Health Companies Inc. trades at an EV/EBITDA multiple of 10.59 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 380.39B versus a market cap of 32.30B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bausch Health Companies Inc. maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,590.90, indicating conservative leverage, while an interest coverage ratio of 1.28 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -4.22, reflecting losses generated across the asset base. The company generates approximately 9.30M in revenue per employee across its workforce of 20,400.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.88 indicates how many times Bausch Health Companies Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bausch Health Companies Inc. recorded 6.31B in income tax expense. The company reported a pretax loss of -12.79B and -19.18B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 25, 2026, Bausch Health Companies Inc.'s stock has declined approximately 23.20% over the past 52 weeks. The 50-day moving average sits at 128.18, while the 200-day moving average is 242.45.

Over the twelve months ended June 30, 2026, Bausch Health Companies Inc. generated 189.62B in revenue and converted that into -19.18B in net income, yielding earnings per share of -51.02. EBITDA reached 35.90B, while operating income came in at 48.24B.

As of June 30, 2026, Bausch Health Companies Inc. holds 31.89B in cash and equivalents against 363.04B in total debt, resulting in a net debt position of 330.49B. Total book value stands at -30.94B, with working capital of 34.56B providing operational flexibility.

Bausch Health Companies Inc. produced 31.45B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.11B in capital expenditures, free cash flow totaled 24.34B - equivalent to 65.16 per share.

Over the twelve months ended June 30, 2026, Bausch Health Companies Inc. posted a gross margin of 71.82, reflecting its pricing power and cost economics. The operating margin of 25.44 and net profit margin of -10.12 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bausch Health Companies Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 75.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 59.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bausch Health Companies Inc. shareholders.

Bausch Health Companies Inc.'s most recent stock split took place on October 5, 2000 with a 1:2 split ratio.

As of June 30, 2026, Bausch Health Companies Inc. has an Altman Z-Score of 0.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.